WallStreetZenWallStreetZen

NASDAQ: NXTC
Nextcure Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NXTC

Based on 1 analyst offering 12 month price targets for Nextcure Inc

Min Forecast
$3.00+340.53%
Avg Forecast
$3.00+340.53%
Max Forecast
$3.00+340.53%

Should I buy or sell NXTC stock?

Based on 1 analyst offering ratings for Nextcure Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NXTC stock forecasts and price targets.

NXTC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-17

1 of 1

Forecast return on equity

Is NXTC forecast to generate an efficient return?

Company
-32.14%
Industry
140.91%
Market
90.47%
NXTC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NXTC forecast to generate an efficient return on assets?

Company
-26.74%
Industry
32.45%
NXTC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NXTC earnings per share forecast

What is NXTC's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.53
Avg 2 year Forecast
-$1.43
Avg 3 year Forecast
-$0.92

NXTC revenue forecast

What is NXTC's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$10.3M
Avg 2 year Forecast
$22.6M
Avg 3 year Forecast
$39.7M

NXTC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NXTC$0.68$3.00+340.53%Buy
CLRB$0.41N/AN/A
CARM$0.45$1.00+121.24%Strong Buy
LGVN$1.30$10.00+669.23%Buy
BCAB$0.41$1.00+146.31%Buy
View Top Biotech Stocks

Nextcure Stock Forecast FAQ

Is Nextcure Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NXTC) stock is to Buy NXTC stock.

Out of 1 analyst, 0 (0%) are recommending NXTC as a Strong Buy, 1 (100%) are recommending NXTC as a Buy, 0 (0%) are recommending NXTC as a Hold, 0 (0%) are recommending NXTC as a Sell, and 0 (0%) are recommending NXTC as a Strong Sell.

If you're new to stock investing, here's how to buy Nextcure stock.

What is NXTC's earnings growth forecast for 2025-2027?

(NASDAQ: NXTC) Nextcure's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Nextcure's earnings in 2025 is -$49,523,000.On average, 3 Wall Street analysts forecast NXTC's earnings for 2025 to be -$42,824,227, with the lowest NXTC earnings forecast at -$45,721,811, and the highest NXTC earnings forecast at -$39,550,769. On average, 2 Wall Street analysts forecast NXTC's earnings for 2026 to be -$40,111,773, with the lowest NXTC earnings forecast at -$49,087,834, and the highest NXTC earnings forecast at -$31,135,712.

In 2027, NXTC is forecast to generate -$25,806,176 in earnings, with the lowest earnings forecast at -$25,806,176 and the highest earnings forecast at -$25,806,176.

What is NXTC's revenue growth forecast for 2028-2030?

(NASDAQ: NXTC) Nextcure's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Nextcure's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NXTC's revenue for 2028 to be $288,916,967, with the lowest NXTC revenue forecast at $288,916,967, and the highest NXTC revenue forecast at $288,916,967. On average, 1 Wall Street analysts forecast NXTC's revenue for 2029 to be $633,934,317, with the lowest NXTC revenue forecast at $633,934,317, and the highest NXTC revenue forecast at $633,934,317.

In 2030, NXTC is forecast to generate $1,113,592,583 in revenue, with the lowest revenue forecast at $1,113,592,583 and the highest revenue forecast at $1,113,592,583.

What is NXTC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: NXTC) forecast ROA is -26.74%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is NXTC's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NXTC price target, the average NXTC price target is $3.00, with the highest NXTC stock price forecast at $3.00 and the lowest NXTC stock price forecast at $3.00.

The Wall Street analyst predicted that Nextcure's share price could reach $3.00 by Mar 17, 2026. The average Nextcure stock price prediction forecasts a potential upside of 340.53% from the current NXTC share price of $0.68.

What is NXTC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NXTC) Nextcure's current Earnings Per Share (EPS) is -$1.76. On average, analysts forecast that NXTC's EPS will be -$1.53 for 2025, with the lowest EPS forecast at -$1.63, and the highest EPS forecast at -$1.41. On average, analysts forecast that NXTC's EPS will be -$1.43 for 2026, with the lowest EPS forecast at -$1.75, and the highest EPS forecast at -$1.11. In 2027, NXTC's EPS is forecast to hit -$0.92 (min: -$0.92, max: -$0.92).

What is NXTC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: NXTC) forecast ROE is -32.14%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.